Articles | Open Access | DOI: https://doi.org/10.37547/TAJMSPR/Volume03Issue06-30

The Role Of Polymorphic Genes Of Matrix Metalloproteinases (MMPS) And Their Tissue Inhibitors In The Development Of Renal Dysfunction In Chronic Glomerulonephritis In Children

jfgfjfgfjdggdygfh@theamericanjournals.com , Head Of The Department Of “Pediatrics”, Siab Medical College, Samarkand, Uzbekistan
Ziyadullaev Sh.Kh. , DSc, Associate Professor, Department № 1 Of “Internal Medicine”, Samarkand State Medical Institute Samarkand, Uzbekistan

Abstract

In children, glomerulonephritis is a disease characterized by rapid progression and complication caused by an irreversible process of the renal glomeruli. Currently, methods of molecular diagnostics have begun to actively develop, which not only complement traditional research methods, but also provide insight from the point of view of molecular pathophysiology. It is expected that a key role in the diagnosis of kidney disease is played by the identification of genes and their changes in the course of the disease, which predict the course of the disease. Changes in chromosomal polymorphic genes of matrix metalloproteinase and its tissue inhibitors, as well as how this change manifests itself in chronic glomerulonephritis, were determined in the prognosis of the disease.

Keywords

Chronic glomerulonephritis, matrix metalloproteinase, tissue inhibitor

References

Bashirova Z.R. (2013). He role of matrix metalloproteinasesin the progression of hereditary kidkidney diseases. Clinical Nephrology, 8–11. (Баширова З. Р, (2013). Роль матриксных металлопротеиназ в прогрессировании наследственных заболеваний почек. Клиническая Нефрология, 8–11.)

Bieniaś B., Sikora P., (2018). Urinary metalloproteinases and tissue inhibitors of metalloproteinasesas potential early biomarkers for renal fibrosisin children with nephrotic syndrome. Medicine, 97 (8), 64-97.

Benjamin A., Michael M. (2015). Ready for prime time fhysiol renal. Molecular nephropathology, 309 (153), 185-188.

Sukhanova G.A, Terentyeva A.A, Kuvshinov N.N. (2015). The role of matrix metalloproteinases and their tissue inhibitors in the development of complications in kidney disease in children. Bulletin of Siberian Medicine, 14 (3), 9-35. (Суханова Г.А., Терентьева А.А., Кувшинов Н.Н. (2015). Роль матриксных металлопротеиназ и их тканевых и ингибиторов в развитии осложнений при заболеваниях почек у детей. Бюллетень сибирской медицины, 14 (3), 9-35)

Djuric T, Zivkovic M, Milosevic B, Andjelevski M. (2014). MMP-1 and-3 haplotype is associated with congenital anomalies of the kidneyand urinary tract. Pediatric Nephrology, 29 (5), 845-879.

Tirikova O.V, I.A. Filatov I.V. (2017). Glomerulonephritis. (1st ed). Irkutsk MU. (Тирикова О.В., Филатова И.В. (2017). Гломерулонефриты. (1-е изд). Иркутск. МУ.)

Grigorkevich O.S., Mokrov G.V., Kosova L.Yu. (2019). Matrix metalloproteinases and their inhibitors. Pharmacokinetics and pharmacodynamics. 2 (5), 3–16. (Григоркевич О.С., Мокров Г.В., Косова Л.Ю. (2019). Матриксные металлопротеиназы и их ингибиторы. Фармакокинетика и фармакодинамика. 2 (5), 3–16.)

Grishchenko A.V, Zhambalova L.M, Dmitriyeva A.V. (2011). Matrix metalloproteinases and their inhibitors in kidney diseases in children. Human Science. 1 (3), 8-27. (Грищенко А.В., Жамбалова Л.М., Дмитриева А.В. (2011). Матриксные металлопротеиназы и их ингибиторы при заболеваниях почек у детей. Науки о человеке, 1 (3), 8-27.)

Ning C, Min Hu, Raouf A. Kh. (2017). Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci. 147-173.

Kobusiak-Prokopowicz M., Krzysztofik J., Kaaz K., Jolda-Mydlowska B., Mysiak A. (2018.) MMP-2 and TIMP-2 in patients with heart failure and chronic kidney disease. Open Medicine,13 (1), 237-246.

Liu C., Lu X., Mao Z., Kang H., Liu H., Pan L., Hu J., Wang L., Zhou F. (2017). The diagnostic accuracy of urinary TIMP-2, for acute kidney injury in adults. A prisma-compliant meta-analysis. Medicine, 96 (27), 74-84.

Levin M., Udi Y., Solomonov I., Sagi I. (2017). Next Generation Matrix Metalloproteinase Inhibitors – Novel Strategies Bring New Prospects. Biochim Biophys, 6 (17), 48-89.

Leontyeva YA., Paunova S.S., Kucherenko A.G., Smirnov I.E., Novikova V.M., Revenkova L.A. et al. (2011). Concentration in the urine matrix metalloproteinase-2 and -9 and their tissue inhibitors in children with pyelonephritis. Clinical Nephrology, 5. 7-54. (Леонтьева Ю.А., Паунова С.С., Кучеренко А.Г., Смирнов И.Е., Новикова В.М., Ревенкова Л.А. и др. (2011). Концентрация в моче матриксных металлопротеиназ-2 и -9 и их тканевых ингибиторов у детей с пиелонефритом. Клин.нефрология. 5, 7-54.)

Li O.A, Bobkova I.N, Kozlovskaya L.V. (2009). Concentration of matrix metalloproteinases and their inhibitorsin urine as an indicator characterizing the course of chronic glomerulonephritis. Clinical Nephrology, 1. 4-50. (Ли О.А., Бобкова И.Н., Козловская Л.В. (2009). Концентрация в моче матриксных металлопротеиназ и их ингибиторов как показатель, характеризующий течение хронического гломерулонефрита. Клин.нефрология, 1. 4-50.)

Musiał K., Bargenda A., Zwolińska D. (2015). Urine matrix metalloproteinases and their extracellular inducer in children with chronic kidney disease. Ren.Fail, 37 (6), 4-18.

Morozov S.L., Dlin V.V., Sukhorukov V.S., Voronkova A.S. (2017). Molecular nephropathology, new opportunities in the diagnosis of kidney disease. Russian Bulletin of Perinatology and Pediatrics, 62 (3), 32-36. (Морозов С.Л., Длин В. В., Сухоруков В.С., Воронкова А.С. (2017). Молекулярная нефропатология, новые возможности в диагностике заболеваний почек. Российский вестник перинатологии и педиатрии, 62 (3), 32-36.)

Markelova E.V., Zdor V.V., Romanchuk A.L., Birko O.N. (2016). Matrix metalloproteinases their relationship with the cytokine system, diagnostic and prognostic potential. Immunopathology, allergology, infectology. 2, 11–22. (Маркелова Е.В., Здор В.В., Романчук А.Л., Бирко О.Н. (2016). Матриксные металлопротеиназы, их взаимосвязь с системой, диагностический и прогностический потенциал. Иммунопатология, аллергология, инфектология. 2, 11–22.)

Melnik A.A. (1018). Focal segmental glomerulosclerosis, genetic analysis and targeted therapy. Clinical Nephrology, 7 (1), 35-49. (Мельник А.А. (1018) Фокально-сегментарный гломерулосклероз, генетический анализ и целевая терапия. Клин.нефрология, 7 (1), 35-49.)

Rakhmanova L.K., Daminov B.T., Karimova U.N. (2017). Chronic glomerulonephritis in children. Methodical manuals. (1st ed.) (Рахманова Л.К., Даминов Б.Т., Каримова У.Н. (2017). Хронический гломерулонефрит у детей. Методическое пособия. (1-е изд.))

Rogova LN., Shesternina N.V., Zamechnik T.V., Fastova I.A. (2011). Matrix metalloproteinases, their role in physiological and pathological processes. Bulletin of New Medical Technologies, 8 (2), 9-86. (Рогова Л.Н., Шестернина Н.В., Замечник Т.В., Фастова И.А. (2011). Матриксные металлопротеиназы, их роль в физиологических и патологических процессах. Вестник новых медицинских технологий, 8 (2), 9-86.)

Robert S., Gicquel T., Victoni T., Valenca S., Barreto E., Bailly- Maitre B., Boichot E., Lagente V. (2016). Involvement of matrix metalloproteinases (MMPs) and inflammasome pathway in molecular mechanisms of fibrosis. Bioscience reports, 36 (4), 30-60.

Sabbatini A.R., Barbaro N.R., Faria A.P., Ritter. A.V., Modolo R. (2017). Matrix metalloproteinase-2–735C/T polymorphism is associated with resistant hypertension in a specialized outpatient clinic in Brazil. Gene, 4 (62), 23–29.

Petrosyan E.K., Belinskaya T.V., Ilyinko L.I., Tsugin, Nosikov V.V. (2006). Polymorphic marker 4G / 5G G PAI-1 gene with chronic glomerulonephritis in children. Nephrology, 10 (15), 62-74. (Петросян Э. К., Белинская Т. В., Ильинко Л.И., Цугин, Носиков В. В. (2006). Полиморфный маркер 4G/5G Г PAI-1 гена с хроническим гломерулонефритом у детей. Нефрология, 10 (15), 62-74.)

Shadrina A.S., Plieva Ya.Z., Kushlinsky D.N., 3 Morozov A.A., Filipenko M.L., Chang V.L., Kushlinsky N.E. (2017). Classification, regulation of activity, genetic polymorphism of matrix metalloproteinases in health and disease. Almanac of Clinical Medicine, 45 (4), 266-279. (Шадрина А.С., Плиева Я.З., Кушлинский Д.Н., Морозов А.А., Филипенко М.Л., Чанг В.Л., Кушлинский Н.Е. (2017). Классификация, регуляция активности, генетический полиморфизм матриксных металлопротеиназ в норме и при патологии. Альманах клинической медицины, 45 (4), 266–279)

Chromek M., Tullus K., Hertting O., Jaremko G., Khalil A., Li YH., Brauner A. (2003). Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in acute pyelonephritis and renal scarring. Pediatr Res, 53 (4), 698–705.

Article Statistics

Copyright License

Download Citations

How to Cite

N.S., B. ., & Sh.Kh., Z. . (2021). The Role Of Polymorphic Genes Of Matrix Metalloproteinases (MMPS) And Their Tissue Inhibitors In The Development Of Renal Dysfunction In Chronic Glomerulonephritis In Children. The American Journal of Medical Sciences and Pharmaceutical Research, 3(06), 195–202. https://doi.org/10.37547/TAJMSPR/Volume03Issue06-30